Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

James O'Reilly

Volunteer Professor of Law
University of Cincinnati - CC
Member of the Law Council

James O'Reilly is a Volunteer Professor of Law at University of Cincinnati, where he has counseled large and small drug, biotech, device and food firms since becoming a full time professor in 1998. Prof. O’Reilly’s 31 books and 137 articles have been widely cited, and as an FDA expert over many years he has led trade association and NGO projects dealing with complex FDA approval, recall and enforcement issues. His book on crisis management and his work on product warnings in text and articles have been widely followed. Prof. O’Reilly’s federal consulting assignments for FTC Chairman's office, EPA, Congressional Office of Compliance and Administration Conference and numerous expert witness and consulting roles have given broad experience on FDA and tort liability issues. He previously worked at The Procter & Gamble Company as Associate General Counsel for 24 years. As the Company's principal regulatory counsel, he worked closely with internal clients and with industry coalitions on EPA, FDA, regulatory agency and Congressional matters. (This is me - Update Profile)


Employment History
1998 - present Volunteer Professor of Law
University of Cincinnati - CC
1974 - 1998 Associate General Counsel
The Procter & Gamble Company

GLG Study Groups with James O'Reilly(?)

GLG NewsSM Analyses by James O'Reilly(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
No Company is Bullet-Proof Against Federal Contractor Risks | 06-10-2008
Analysis of: U.S. sues Honeywell over bullet-proof vests | www.latimes.com
Author: James O'Reilly, Volunteer Professor of Law, University of Cincinnati - CC

Product liability exposure of new materials makers can be severe, especially with fatal consequences of failures Internal memos re product problems can shoot company in the foot; prudent firms have a plan for controlling open-ended speculative memos in an instant-message environment Major PR and govt....

Controversy Bred By Under-Regulation: Are Genes Too Casual? | 02-04-2008
Author: James O'Reilly, Volunteer Professor of Law, University of Cincinnati - CC

Recent reports by a federal study panel, addressed in stories in the NY Times and other sources, highlight one more gap between expectations and reality in the resource-starved federal safety net for consumers. Much less is being done to oversee Gene Test kits than consumers may expect; eventually there...

Paint Industry Needs Global Lead Settlement Quickly | 05-09-2007
Analysis of: Lead paint industry on the defensive | www.lawyersweeklyusa.com
Author: James O'Reilly, Volunteer Professor of Law, University of Cincinnati - CC

"Son of Asbestos" claims may sound extreme; but the lead paint makers would be prudent to collectively negotiate and fund a 50-state settlement that follow the tobacco companies' model and avoids the bankruptcy model of the asbestos-using firms. Lead injury awareness has increased and demands for public...

GLG InstituteSM Seminars with James O'Reilly(?)

 

Recent Seminars

GLGi: FDA Recalls
Los Angeles, 08-25-2005
GLGi: FDA Recalls
San Francisco, 08-25-2005
View All GLG InstituteSM Seminars with James O'Reilly

Request a project with James O'Reilly








GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics